Pneumonia Vaccine Market – Industry Structure Evaluation, Demand Drivers Analysis, Regional Growth Analysis and Identification, Competitive Positioning / Landscape Review & Global Market Size Forecast to 2029
5%
CAGR (2022-2029)
9.01 USD Bn.
Market Size
302
Report Pages
149
Market Tables
Overview
Pneumonia Vaccine Market is expected to reach US$ 13.31 Bn. at a CAGR of 5 during the forecast period 2029.
Pneumococcal disease caused by streptococcus pneumonia is the prominent cause of pneumonia, which results in the greatest number of deaths in children under five years of age globally. The WHO recommends that pneumococcal vaccines be introduced into all national immunisation programs, particularly in economies with high child mortality.
To know about the Research Methodology :- Request Free Sample Report
The report study has analyzed revenue impact of COVID -19 pandemic on the sales revenue of market leaders, market followers and market disrupters in the report and same is reflected in our analysis.
The report covers all the trends and technologies playing a major role in the growth of the pneumonia vaccine market over the forecast period. It highlights the drivers, restraints, and opportunities expected to influence market growth during 2021-2029. As pharmaceutical companies are being reluctant to invest in production of new vaccines because of very fewer returns, vendors are opting advanced market commitment (AMC), an innovative financing program under which international agencies pay a premium above the incremental production cost for initial doses sold to emerging economies and in exchange, vendors agree to continue supply of vaccines at sustainable costs for long term.
Based on the vaccine type, 13-valent PCV vaccine segment is expected to account for the largest xx% market share by 2029. PVC13 provides a significant benefit for preventing pneumonia and invasive diseases caused by Streptococcus pneumonia in adults and children. The CDC (Centers for Disease Control and Prevention) PCV13 vaccines for children below 2 and adults above 65 years of age. Additionally, it is now recommended that adults above 65 and older to get both PCV13 and PPSV23 vaccine for better immunogenicity against many serotypes of pneumococcus.
The report offers a brief analysis of the major regions in the pneumonia vaccine market, namely, APAC, Europe, North America, Latin America, and the Middle East & Africa. North America held the largest xx% share in the pneumococcal vaccines market in 2017. Growing government funding and awareness programs in the region are fueling the market. Such as, PCV has been introduced in the routine immunization program to curb the burden of pneumococcus diseases.
The competitive landscape section in the pneumonia vaccine market proposals a deep dive into the profiles of the leading companies operating in the global market landscape. It offers captivating insights on the key developments, differential strategies, and other crucial aspects about the key players having a stronghold in the pneumonia vaccine market. In January 2018, Pfizer reduced the price of its PCV-13 4 dose vial vaccine for GAVI-supported countries from $3.05 to $2.95 per dose. Growing addition of pneumococcal vaccine in national immunization programs is favoring the growth of pneumococcal vaccines market. According to the World Health Organization (WHO) until 2017, a total of 138 economies are introduced with pneumococcal vaccines in their national immunization program.
The objective of the report is to present comprehensive analysis of Global Pneumonia Vaccine Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers the all the aspects of industry with dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give clear futuristic view of the industry to the decision makers.
The report also helps in understanding Global Pneumonia Vaccine Market dynamics, structure by analyzing the market segments, and project the Global Pneumonia Vaccine Market size. Clear representation of competitive analysis of key players by type, price, financial position, product portfolio, growth strategies, and regional presence in the Global Pneumonia Vaccine Market make the report investor’s guide.
Scope of the Global Pneumonia Vaccine Market: Inquire before buying
| Global Pneumonia Vaccine Market | |||
|---|---|---|---|
| Report Coverage | Details | ||
| Base Year: | 2021 | Forecast Period: | 2022-2029 |
| Historical Data: | 2017 to 2021 | Market Size in 2021: | US $ 9.01Bn. |
| Forecast Period 2022 to 2029 CAGR: | 5% | Market Size in 2029: | US $ 13.31 Bn. |
| Segments Covered: | by Vaccine Type | • Pneumococcal Conjugate Vaccine • Pneumococcal Polysaccharide Vaccine |
|
| by Product Type | • Prevnar 13 • Synflorix • Pneumovax 23 |
||
| by Sector | • Public • Private |
||
| by Distribution Channel | •Distribution Partner Companies • Non-governmental Organizations (NGO) • Government Authorities |
||
Pneumonia Vaccine Market, by Region
• North America
• Asia Pacific
• Europe
• Middle East & Africa
• South America
Pneumonia Vaccine Market Key Players are:
• Bayer AG
• GlaxoSmithKline plc
• Pfizer Inc.
• Nuron Biotech Inc.
• CSL Ltd.
• Biomed Pvt. Ltd.
• Serum Institute of India Pvt. Ltd.
• Sanofi Pasteur Inc.
• JN-International Medical Corporation
• Merck & Co., Inc.
• LG Chem Ltd.
• Panacea Biotec Limited
• Pnuvax Incorporated
• Shenzhen Kangtai Biological Products Co., Ltd.
• SK Bioscience
• Walvax Biotechnology Co., Ltd.
Frequently Asked questions
1. What is the market size of the Global Pneumonia Vaccine Market in 2021?
Ans. The market size Global Pneumonia Vaccine Market in 2021 was US$ 9.01 Billion.
2. What are the different segments of the Global Pneumonia Vaccine Market?
Ans. The Global Pneumonia Vaccine Market is divided into Sector, Product, Vaccine Type and Distribution Channel.
3. What is the study period of this market?
Ans. The Global Pneumonia Vaccine Market will be studied from 2021 to 2029.
4. Which region is expected to hold the highest Global Pneumonia Vaccine Market share?
Ans. The Asia Pacific dominates the market share in the market.
5. What is the Forecast Period of Global Pneumonia Vaccine Market?
Ans. The Forecast Period of the market is 2022-2029 in the market.
Table of Contents
Global Pneumonia Vaccine Market
1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
1.3. Research Objectives
2. Assumptions and Research Methodology
2.1. Report Assumptions
2.2. Abbreviations
2.3. Research Methodology
2.3.1. Secondary Research
2.3.1.1. Secondary data
2.3.1.2. Secondary Sources
2.3.2. Primary Research
2.3.2.1. Data from Primary Sources
2.3.2.2. Breakdown of Primary Sources
3. Executive Summary: Global Pneumonia Vaccine Market Size, by Market Value (US$ Bn)
4. Market Overview
4.1. Introduction
4.2. Market Indicator
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.2.4. Challenges
4.3. Porter’s Analysis
4.4. Value Chain Analysis
4.5. Market Risk Analysis
4.6. SWOT Analysis
4.7. Industry Trends and Emerging Technologies
5. Supply Side and Demand Side Indicators
6. Global Pneumonia Vaccine Market Analysis and Forecast
6.1. Global Pneumonia Vaccine Market Size & Y-o-Y Growth Analysis
6.1.1. North America
6.1.2. Europe
6.1.3. Asia Pacific
6.1.4. Middle East & Africa
6.1.5. South America
7. Global Pneumonia Vaccine Market Analysis and Forecast, By Vaccine Type
7.1. Introduction and Definition
7.2. Key Findings
7.3. Global Pneumonia Vaccine Market Value Share Analysis, By Vaccine Type
7.4. Global Pneumonia Vaccine Market Size (US$ Bn) Forecast, By Vaccine Type
7.5. Global Pneumonia Vaccine Market Analysis, By Vaccine Type
7.6. Global Pneumonia Vaccine Market Attractiveness Analysis, By Vaccine Type
8. Global Pneumonia Vaccine Market Analysis and Forecast, By Sector
8.1. Introduction and Definition
8.2. Key Findings
8.3. Global Pneumonia Vaccine Market Value Share Analysis, By Sector
8.4. Global Pneumonia Vaccine Market Size (US$ Bn) Forecast, By Sector
8.5. Global Pneumonia Vaccine Market Analysis, By Sector
8.6. Global Pneumonia Vaccine Market Attractiveness Analysis, By Sector
9. Global Pneumonia Vaccine Market Analysis and Forecast, By Product Type
9.1. Introduction and Definition
9.2. Key Findings
9.3. Global Pneumonia Vaccine Market Value Share Analysis, By Product Type
9.4. Global Pneumonia Vaccine Market Size (US$ Bn) Forecast, By Product Type
9.5. Global Pneumonia Vaccine Market Analysis, By Product Type
9.6. Global Pneumonia Vaccine Market Attractiveness Analysis, By Product Type
10. Global Pneumonia Vaccine Market Analysis and Forecast, By Distribution Channel
10.1. Introduction and Definition
10.2. Key Findings
10.3. Global Pneumonia Vaccine Market Value Share Analysis, By Distribution Channel
10.4. Global Pneumonia Vaccine Market Size (US$ Bn) Forecast, By Distribution Channel
10.5. Global Pneumonia Vaccine Market Analysis, By Distribution Channel
10.6. Global Pneumonia Vaccine Market Attractiveness Analysis, By Distribution Channel
11. Global Pneumonia Vaccine Market Analysis, by Region
11.1. Global Pneumonia Vaccine Market Value Share Analysis, by Region
11.2. Global Pneumonia Vaccine Market Size (US$ Bn) Forecast, by Region
11.3. Global Pneumonia Vaccine Market Attractiveness Analysis, by Region
12. North America Pneumonia Vaccine Market Analysis
12.1. Key Findings
12.2. North America Pneumonia Vaccine Market Overview
12.3. North America Pneumonia Vaccine Market Value Share Analysis, By Vaccine Type
12.4. North America Pneumonia Vaccine Market Forecast, By Vaccine Type
12.4.1. Pneumococcal Conjugate Vaccine
12.4.2. Pneumococcal Polysaccharide Vaccine
12.5. North America Pneumonia Vaccine Market Value Share Analysis, By Sector
12.6. North America Pneumonia Vaccine Market Forecast, By Sector
12.6.1. Public
12.6.2. Private
12.7. North America Pneumonia Vaccine Market Value Share Analysis, By Product Type
12.8. North America Pneumonia Vaccine Market Forecast, By Product Type
12.8.1. Prevnar 13
12.8.2. Synflorix
12.8.3. Pneumovax 23
12.9. North America Pneumonia Vaccine Market Value Share Analysis, By Distribution Channel
12.10. North America Pneumonia Vaccine Market Forecast, By Distribution Channel
12.10.1. Distribution Partner Companies
12.10.2. Non-governmental Organizations (NGO)
12.10.3. Government Authorities
12.11. North America Pneumonia Vaccine Market Value Share Analysis, by Country
12.12. North America Pneumonia Vaccine Market Forecast, by Country
12.12.1. U.S.
12.12.2. Canada
12.13. North America Pneumonia Vaccine Market Analysis, by Country
12.14. U.S. Pneumonia Vaccine Market Forecast, By Vaccine Type
12.14.1. Pneumococcal Conjugate Vaccine
12.14.2. Pneumococcal Polysaccharide Vaccine
12.15. U.S. Pneumonia Vaccine Market Forecast, By Sector
12.15.1. Public
12.15.2. Private
12.16. U.S. Pneumonia Vaccine Market Forecast, By Product Type
12.16.1. Prevnar 13
12.16.2. Synflorix
12.16.3. Pneumovax 23
12.17. U.S. Pneumonia Vaccine Market Forecast, By Distribution Channel
12.17.1. Distribution Partner Companies
12.17.2. Non-governmental Organizations (NGO)
12.17.3. Government Authorities
12.18. Canada Pneumonia Vaccine Market Forecast, By Vaccine Type
12.18.1. Pneumococcal Conjugate Vaccine
12.18.2. Pneumococcal Polysaccharide Vaccine
12.19. Canada Pneumonia Vaccine Market Forecast, By Sector
12.19.1. Public
12.19.2. Private
12.20. Canada Pneumonia Vaccine Market Forecast, By Product Type
12.20.1. Prevnar 13
12.20.2. Synflorix
12.20.3. Pneumovax 23
12.21. Canada Pneumonia Vaccine Market Forecast, By Distribution Channel
12.21.1. Distribution Partner Companies
12.21.2. Non-governmental Organizations (NGO)
12.21.3. Government Authorities
12.22. North America Pneumonia Vaccine Market Attractiveness Analysis
12.22.1. By Vaccine Type
12.22.2. By Sector
12.22.3. By Product Type
12.22.4. By Distribution Channel
12.23. PEST Analysis
12.24. Key Trends
12.25. Key Developments
13. Europe Pneumonia Vaccine Market Analysis
13.1. Key Findings
13.2. Europe Pneumonia Vaccine Market Overview
13.3. Europe Pneumonia Vaccine Market Value Share Analysis, By Vaccine Type
13.4. Europe Pneumonia Vaccine Market Forecast, By Vaccine Type
13.4.1. Pneumococcal Conjugate Vaccine
13.4.2. Pneumococcal Polysaccharide Vaccine
13.5. Europe Pneumonia Vaccine Market Value Share Analysis, By Sector
13.6. Europe Pneumonia Vaccine Market Forecast, By Sector
13.6.1. Public
13.6.2. Private
13.7. Europe Pneumonia Vaccine Market Value Share Analysis, By Product Type
13.8. Europe Pneumonia Vaccine Market Forecast, By Product Type
13.8.1. Prevnar 13
13.8.2. Synflorix
13.8.3. Pneumovax 23
13.9. Europe Pneumonia Vaccine Market Value Share Analysis, By Distribution Channel
13.10. Europe Pneumonia Vaccine Market Forecast, By Distribution Channel
13.10.1. Distribution Partner Companies
13.10.2. Non-governmental Organizations (NGO)
13.10.3. Government Authorities
13.11. Europe Pneumonia Vaccine Market Value Share Analysis, by Country
13.12. Europe Pneumonia Vaccine Market Forecast, by Country
13.12.1. Germany
13.12.2. U.K.
13.12.3. France
13.12.4. Italy
13.12.5. Spain
13.12.6. Rest of Europe
13.13. Europe Pneumonia Vaccine Market Analysis, by Country
13.14. Germany Pneumonia Vaccine Market Forecast, By Vaccine Type
13.14.1. Pneumococcal Conjugate Vaccine
13.14.2. Pneumococcal Polysaccharide Vaccine
13.15. Germany Pneumonia Vaccine Market Forecast, By Sector
13.15.1. Public
13.15.2. Private
13.16. Germany Pneumonia Vaccine Market Forecast, By Product Type
13.16.1. Prevnar 13
13.16.2. Synflorix
13.16.3. Pneumovax 23
13.17. Germany Pneumonia Vaccine Market Forecast, By Distribution Channel
13.17.1. Distribution Partner Companies
13.17.2. Non-governmental Organizations (NGO)
13.17.3. Government Authorities
13.18. U.K. Pneumonia Vaccine Market Forecast, By Vaccine Type
13.18.1. Pneumococcal Conjugate Vaccine
13.18.2. Pneumococcal Polysaccharide Vaccine
13.19. U.K. Pneumonia Vaccine Market Forecast, By Sector
13.19.1. Public
13.19.2. Private
13.20. U.K. Pneumonia Vaccine Market Forecast, By Product Type
13.20.1. Prevnar 13
13.20.2. Synflorix
13.20.3. Pneumovax 23
13.21. U.K. Pneumonia Vaccine Market Forecast, By Distribution Channel
13.21.1. Distribution Partner Companies
13.21.2. Non-governmental Organizations (NGO)
13.21.3. Government Authorities
13.22. France Pneumonia Vaccine Market Forecast, By Vaccine Type
13.22.1. Pneumococcal Conjugate Vaccine
13.22.2. Pneumococcal Polysaccharide Vaccine
13.23. France Pneumonia Vaccine Market Forecast, By Sector
13.23.1. Public
13.23.2. Private
13.24. France Pneumonia Vaccine Market Forecast, By Product Type
13.24.1. Prevnar 13
13.24.2. Synflorix
13.24.3. Pneumovax 23
13.25. France Pneumonia Vaccine Market Forecast, By Distribution Channel
13.25.1. Distribution Partner Companies
13.25.2. Non-governmental Organizations (NGO)
13.25.3. Government Authorities
13.26. Italy Pneumonia Vaccine Market Forecast, By Vaccine Type
13.26.1. Pneumococcal Conjugate Vaccine
13.26.2. Pneumococcal Polysaccharide Vaccine
13.27. Italy Pneumonia Vaccine Market Forecast, By Sector
13.27.1. Public
13.27.2. Private
13.28. Italy Pneumonia Vaccine Market Forecast, By Product Type
13.28.1. Prevnar 13
13.28.2. Synflorix
13.28.3. Pneumovax 23
13.29. Italy Pneumonia Vaccine Market Forecast, By Distribution Channel
13.29.1. Distribution Partner Companies
13.29.2. Non-governmental Organizations (NGO)
13.29.3. Government Authorities
13.30. Spain Pneumonia Vaccine Market Forecast, By Vaccine Type
13.30.1. Pneumococcal Conjugate Vaccine
13.30.2. Pneumococcal Polysaccharide Vaccine
13.31. Spain Pneumonia Vaccine Market Forecast, By Sector
13.31.1. Public
13.31.2. Private
13.32. Spain Pneumonia Vaccine Market Forecast, By Product Type
13.32.1. Prevnar 13
13.32.2. Synflorix
13.32.3. Pneumovax 23
13.33. Spain Pneumonia Vaccine Market Forecast, By Distribution Channel
13.33.1. Distribution Partner Companies
13.33.2. Non-governmental Organizations (NGO)
13.33.3. Government Authorities
13.34. Rest of Europe Pneumonia Vaccine Market Forecast, By Vaccine Type
13.34.1. Pneumococcal Conjugate Vaccine
13.34.2. Pneumococcal Polysaccharide Vaccine
13.35. Rest of Europe Pneumonia Vaccine Market Forecast, By Sector
13.35.1. Public
13.35.2. Private
13.36. Rest of Europe Pneumonia Vaccine Market Forecast, By Product Type
13.36.1. Prevnar 13
13.36.2. Synflorix
13.36.3. Pneumovax 23
13.37. Rest Of Europe Pneumonia Vaccine Market Forecast, By Distribution Channel
13.37.1. Distribution Partner Companies
13.37.2. Non-governmental Organizations (NGO)
13.37.3. Government Authorities
13.38. Europe Pneumonia Vaccine Market Attractiveness Analysis
13.38.1. By Vaccine Type
13.38.2. By Sector
13.38.3. By Product Type
13.38.4. By Distribution Channel
13.39. PEST Analysis
13.40. Key Trends
13.41. Key Developments
14. Asia Pacific Pneumonia Vaccine Market Analysis
14.1. Key Findings
14.2. Asia Pacific Pneumonia Vaccine Market Overview
14.3. Asia Pacific Pneumonia Vaccine Market Value Share Analysis, By Vaccine Type
14.4. Asia Pacific Pneumonia Vaccine Market Forecast, By Vaccine Type
14.4.1. Pneumococcal Conjugate Vaccine
14.4.2. Pneumococcal Polysaccharide Vaccine
14.5. Asia Pacific Pneumonia Vaccine Market Value Share Analysis, By Sector
14.6. Asia Pacific Pneumonia Vaccine Market Forecast, By Sector
14.6.1. Public
14.6.2. Private
14.7. Asia Pacific Pneumonia Vaccine Market Value Share Analysis, By Product Type
14.8. Asia Pacific Pneumonia Vaccine Market Forecast, By Product Type
14.8.1. Prevnar 13
14.8.2. Synflorix
14.8.3. Pneumovax 23
14.9. Asia Pacific Pneumonia Vaccine Market Value Share Analysis, By Distribution Channel
14.10. Asia Pacific Pneumonia Vaccine Market Forecast, By Distribution Channel
14.10.1. Distribution Partner Companies
14.10.2. Non-governmental Organizations (NGO)
14.10.3. Government Authorities
14.11. Asia Pacific Pneumonia Vaccine Market Value Share Analysis, by Country
14.12. Asia Pacific Pneumonia Vaccine Market Forecast, by Country
14.12.1. China
14.12.2. India
14.12.3. Japan
14.12.4. ASEAN
14.12.5. Rest of Asia Pacific
14.13. Asia Pacific Pneumonia Vaccine Market Analysis, by Country
14.14. China Pneumonia Vaccine Market Forecast, By Vaccine Type
14.14.1. Pneumococcal Conjugate Vaccine
14.14.2. Pneumococcal Polysaccharide Vaccine
14.15. China Pneumonia Vaccine Market Forecast, By Sector
14.15.1. Public
14.15.2. Private
14.16. China Pneumonia Vaccine Market Forecast, By Product Type
14.16.1. Prevnar 13
14.16.2. Synflorix
14.16.3. Pneumovax 23
14.17. China Pneumonia Vaccine Market Forecast, By Distribution Channel
14.17.1. Distribution Partner Companies
14.17.2. Non-governmental Organizations (NGO)
14.17.3. Government Authorities
14.18. India Pneumonia Vaccine Market Forecast, By Vaccine Type
14.18.1. Pneumococcal Conjugate Vaccine
14.18.2. Pneumococcal Polysaccharide Vaccine
14.19. India Pneumonia Vaccine Market Forecast, By Sector
14.19.1. Public
14.19.2. Private
14.20. India Pneumonia Vaccine Market Forecast, By Product Type
14.20.1. Prevnar 13
14.20.2. Synflorix
14.20.3. Pneumovax 23
14.21. India Pneumonia Vaccine Market Forecast, By Distribution Channel
14.21.1. Distribution Partner Companies
14.21.2. Non-governmental Organizations (NGO)
14.21.3. Government Authorities
14.22. Japan Pneumonia Vaccine Market Forecast, By Vaccine Type
14.22.1. Pneumococcal Conjugate Vaccine
14.22.2. Pneumococcal Polysaccharide Vaccine
14.23. Japan Pneumonia Vaccine Market Forecast, By Sector
14.23.1. Public
14.23.2. Private
14.24. Japan Pneumonia Vaccine Market Forecast, By Product Type
14.24.1. Prevnar 13
14.24.2. Synflorix
14.24.3. Pneumovax 23
14.25. Japan Pneumonia Vaccine Market Forecast, By Distribution Channel
14.25.1. Distribution Partner Companies
14.25.2. Non-governmental Organizations (NGO)
14.25.3. Government Authorities
14.26. ASEAN Pneumonia Vaccine Market Forecast, By Vaccine Type
14.26.1. Pneumococcal Conjugate Vaccine
14.26.2. Pneumococcal Polysaccharide Vaccine
14.27. ASEAN Pneumonia Vaccine Market Forecast, By Sector
14.27.1. Public
14.27.2. Private
14.28. ASEAN Pneumonia Vaccine Market Forecast, By Product Type
14.28.1. Prevnar 13
14.28.2. Synflorix
14.28.3. Pneumovax 23
14.29. ASEAN Pneumonia Vaccine Market Forecast, By Distribution Channel
14.29.1. Distribution Partner Companies
14.29.2. Non-governmental Organizations (NGO)
14.29.3. Government Authorities
14.30. Rest of Asia Pacific Pneumonia Vaccine Market Forecast, By Vaccine Type
14.30.1. Pneumococcal Conjugate Vaccine
14.30.2. Pneumococcal Polysaccharide Vaccine
14.31. Rest of Asia Pacific Pneumonia Vaccine Market Forecast, By Sector
14.31.1. Public
14.31.2. Private
14.32. Rest of Asia Pacific Pneumonia Vaccine Market Forecast, By Product Type
14.32.1. Prevnar 13
14.32.2. Synflorix
14.32.3. Pneumovax 23
14.33. Rest of Asia Pacific Pneumonia Vaccine Market Forecast, By Distribution Channel
14.33.1. Distribution Partner Companies
14.33.2. Non-governmental Organizations (NGO)
14.33.3. Government Authorities
14.34. Asia Pacific Pneumonia Vaccine Market Attractiveness Analysis
14.34.1. By Vaccine Type
14.34.2. By Sector
14.34.3. By Product Type
14.34.4. By Distribution Channel
14.35. PEST Analysis
14.36. Key Trends
14.37. Key Developments
15. Middle East & Africa Pneumonia Vaccine Market Analysis
15.1. Key Findings
15.2. Middle East & Africa Pneumonia Vaccine Market Overview
15.3. Middle East & Africa Pneumonia Vaccine Market Value Share Analysis, By Vaccine Type
15.4. Middle East & Africa Pneumonia Vaccine Market Forecast, By Vaccine Type
15.4.1. Pneumococcal Conjugate Vaccine
15.4.2. Pneumococcal Polysaccharide Vaccine
15.5. Middle East & Africa Pneumonia Vaccine Market Value Share Analysis, By Sector
15.6. Middle East & Africa Pneumonia Vaccine Market Forecast, By Sector
15.6.1. Public
15.6.2. Private
15.7. Middle East & Africa Pneumonia Vaccine Market Value Share Analysis, By Product Type
15.8. Middle East & Africa Pneumonia Vaccine Market Forecast, By Product Type
15.8.1. Prevnar 13
15.8.2. Synflorix
15.8.3. Pneumovax 23
15.9. Middle East & Africa Pneumonia Vaccine Market Value Share Analysis, By Distribution Channel
15.10. Middle East & Africa Pneumonia Vaccine Market Forecast, By Distribution Channel
15.10.1. Distribution Partner Companies
15.10.2. Non-governmental Organizations (NGO)
15.10.3. Government Authorities
15.11. Middle East & Africa Pneumonia Vaccine Market Value Share Analysis, by Country
15.12. Middle East & Africa Pneumonia Vaccine Market Forecast, by Country
15.12.1. GCC
15.12.2. South Africa
15.12.3. Rest of Middle East & Africa
15.13. Middle East & Africa Pneumonia Vaccine Market Analysis, by Country
15.14. GCC Pneumonia Vaccine Market Forecast, By Vaccine Type
15.14.1. Pneumococcal Conjugate Vaccine
15.14.2. Pneumococcal Polysaccharide Vaccine
15.15. GCC Pneumonia Vaccine Market Forecast, By Sector
15.15.1. Public
15.15.2. Private
15.16. GCC Pneumonia Vaccine Market Forecast, By Product Type
15.16.1. Prevnar 13
15.16.2. Synflorix
15.16.3. Pneumovax 23
15.17. GCC Pneumonia Vaccine Market Forecast, By Distribution Channel
15.17.1. Distribution Partner Companies
15.17.2. Non-governmental Organizations (NGO)
15.17.3. Government Authorities
15.18. South Africa Pneumonia Vaccine Market Forecast, By Vaccine Type
15.18.1. Pneumococcal Conjugate Vaccine
15.18.2. Pneumococcal Polysaccharide Vaccine
15.19. South Africa Pneumonia Vaccine Market Forecast, By Sector
15.19.1. Public
15.19.2. Private
15.20. South Africa Pneumonia Vaccine Market Forecast, By Product Type
15.20.1. Prevnar 13
15.20.2. Synflorix
15.20.3. Pneumovax 23
15.21. South Africa Pneumonia Vaccine Market Forecast, By Distribution Channel
15.21.1. Distribution Partner Companies
15.21.2. Non-governmental Organizations (NGO)
15.21.3. Government Authorities
15.22. Rest of Middle East & Africa Pneumonia Vaccine Market Forecast, By Vaccine Type
15.22.1. Pneumococcal Conjugate Vaccine
15.22.2. Pneumococcal Polysaccharide Vaccine
15.23. Rest of Middle East & Africa Pneumonia Vaccine Market Forecast, By Sector
15.23.1. Public
15.23.2. Private
15.24. Rest of Middle East & Africa Pneumonia Vaccine Market Forecast, By Product Type
15.24.1. Prevnar 13
15.24.2. Synflorix
15.24.3. Pneumovax 23
15.25. Rest of Middle East & Africa Pneumonia Vaccine Market Forecast, By Distribution Channel
15.25.1. Distribution Partner Companies
15.25.2. Non-governmental Organizations (NGO)
15.25.3. Government Authorities
15.26. Middle East & Africa Pneumonia Vaccine Market Attractiveness Analysis
15.26.1. By Vaccine Type
15.26.2. By Sector
15.26.3. By Product Type
15.26.4. By Distribution Channel
15.27. PEST Analysis
15.28. Key Trends
15.29. Key Developments
16. South America Pneumonia Vaccine Market Analysis
16.1. Key Findings
16.2. South America Pneumonia Vaccine Market Overview
16.3. South America Pneumonia Vaccine Market Value Share Analysis, By Vaccine Type
16.4. South America Pneumonia Vaccine Market Forecast, By Vaccine Type
16.4.1. Pneumococcal Conjugate Vaccine
16.4.2. Pneumococcal Polysaccharide Vaccine
16.5. South America Pneumonia Vaccine Market Value Share Analysis, By Sector
16.6. South America Pneumonia Vaccine Market Forecast, By Sector
16.6.1. Public
16.6.2. Private
16.7. South America Pneumonia Vaccine Market Value Share Analysis, By Product Type
16.8. South America Pneumonia Vaccine Market Forecast, By Product Type
16.8.1. Prevnar 13
16.8.2. Synflorix
16.8.3. Pneumovax 23
16.9. South America Pneumonia Vaccine Market Value Share Analysis, By Distribution Channel
16.10. South America Pneumonia Vaccine Market Forecast, By Distribution Channel
16.10.1. Distribution Partner Companies
16.10.2. Non-governmental Organizations (NGO)
16.10.3. Government Authorities
16.11. South America Pneumonia Vaccine Market Value Share Analysis, by Country
16.12. South America Pneumonia Vaccine Market Forecast, by Country
16.12.1. Brazil
16.12.2. Mexico
16.12.3. Rest of South America
16.13. South America Pneumonia Vaccine Market Analysis, by Country
16.14. Brazil Pneumonia Vaccine Market Forecast, By Vaccine Type
16.14.1. Pneumococcal Conjugate Vaccine
16.14.2. Pneumococcal Polysaccharide Vaccine
16.15. Brazil Pneumonia Vaccine Market Forecast, By Sector
16.15.1. Public
16.15.2. Private
16.16. Brazil Pneumonia Vaccine Market Forecast, By Product Type
16.16.1. Prevnar 13
16.16.2. Synflorix
16.16.3. Pneumovax 23
16.17. Brazil Pneumonia Vaccine Market Forecast, By Distribution Channel
16.17.1. Distribution Partner Companies
16.17.2. Non-governmental Organizations (NGO)
16.17.3. Government Authorities
16.18. Mexico Pneumonia Vaccine Market Forecast, By Vaccine Type
16.18.1. Pneumococcal Conjugate Vaccine
16.18.2. Pneumococcal Polysaccharide Vaccine
16.19. Mexico Pneumonia Vaccine Market Forecast, By Sector
16.19.1. Public
16.19.2. Private
16.20. Mexico Pneumonia Vaccine Market Forecast, By Product Type
16.20.1. Prevnar 13
16.20.2. Synflorix
16.20.3. Pneumovax 23
16.21. Mexico Pneumonia Vaccine Market Forecast, By Distribution Channel
16.21.1. Distribution Partner Companies
16.21.2. Non-governmental Organizations (NGO)
16.21.3. Government Authorities
16.22. Rest of South America Pneumonia Vaccine Market Forecast, By Vaccine Type
16.22.1. Pneumococcal Conjugate Vaccine
16.22.2. Pneumococcal Polysaccharide Vaccine
16.23. Rest of South America Pneumonia Vaccine Market Forecast, By Sector
16.23.1. Public
16.23.2. Private
16.24. Rest of South America Pneumonia Vaccine Market Forecast, By Product Type
16.24.1. Prevnar 13
16.24.2. Synflorix
16.24.3. Pneumovax 23
16.25. Rest of South America Pneumonia Vaccine Market Forecast, By Distribution Channel
16.25.1. Distribution Partner Companies
16.25.2. Non-governmental Organizations (NGO)
16.25.3. Government Authorities
16.26. South America Pneumonia Vaccine Market Attractiveness Analysis
16.26.1. By Vaccine Type
16.26.2. By Sector
16.26.3. By Product Type
16.26.4. By Distribution Channel
16.27. PEST Analysis
16.28. Key Trends
16.29. Key Developments
17. Company Profiles
17.1. Market Share Analysis, by Company
17.2. Competition Matrix
17.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment
17.2.2. New Product Launches and Product Enhancements
17.2.3. Market Consolidation
17.2.3.1. M&A by Regions, Investment and Applications
17.2.3.2. M&A Key Players, Forward Integration and Backward
Integration
17.3. Company Profiles: Key Players
17.3.1. Bayer AG
17.3.1.1. Company Overview
17.3.1.2. Financial Overview
17.3.1.3. Product Portfolio
17.3.1.4. Business Strategy
17.3.1.5. Recent Developments
17.3.1.6. Company Footprint
17.3.2. GlaxoSmithKline plc
17.3.3. Pfizer Inc.
17.3.4. Nuron Biotech Inc.
17.3.5. CSL Ltd.
17.3.6. Biomed Pvt. Ltd.
17.3.7. Serum Institute of India Pvt. Ltd.
17.3.8. Sanofi Pasteur Inc.
17.3.9. JN-International Medical Corporation
17.3.10. Merck & Co., Inc.
17.3.11. LG Chem Ltd.
17.3.12. Panacea Biotec Limited
17.3.13. Pnuvax Incorporated
17.3.14. Shenzhen Kangtai Biological Products Co., Ltd.
17.3.15. SK Bioscience
17.3.16. Walvax Biotechnology Co., Ltd.
18. Primary Key Insights